-
Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization
Wednesday, September 9, 2020 - 11:09am | 324Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to manufacture Inovio's DNA COVID-19 vaccine. The Inovio Analyst: H.C. Wainwright analyst Raghuram Selvaraju...
-
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally
Monday, June 29, 2020 - 10:37am | 496Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%. Much of the upside stemmed from a $71-million DoD contract award for its COVID-19 vaccine delivery device. The...
-
Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug
Monday, June 22, 2020 - 9:13am | 457The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK). What Happened: The Solana Beach, California-based specialty pharma company said the FDA gave its nod for its Gimoti nasal spray that would allow the company to commercially market it in the U.S...
-
Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit
Thursday, June 11, 2020 - 11:31am | 305Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19. What Happened: Sorrento said it has filed for an Emergency Use Authorization for its in vitro diagnostic test kit...
-
Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline
Thursday, May 21, 2020 - 2:52pm | 543A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus...
-
Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options
Monday, May 18, 2020 - 2:36pm | 476Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection. The Sorrento Analyst H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $...
-
Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report
Tuesday, May 12, 2020 - 2:49pm | 550Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate. The Inovio Analysts Stifel analyst Stephen Wiley maintained a Buy rating and $19 price target for Inovio...
-
Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine
Wednesday, April 29, 2020 - 2:20pm | 574Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and positive Phase 1/2a data for its MERS coronavirus vaccine INO-4700 on Tuesday. The Inovio Analysts Cantor Fitzgerald analyst...
-
Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption
Wednesday, October 23, 2019 - 4:27pm | 1374Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. The Morris Plains, New Jersey-based company was founded in 1982 and has yet to market a commercial product. Its investigational therapies include ADCs that are...
-
Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More
Monday, September 30, 2019 - 1:13pm | 1247The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence takes place, the gathering brings together pharma and biotech companies focused...
-
Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation
Wednesday, December 26, 2018 - 1:31pm | 361Stemline Therapeutics Inc (NASDAQ: STML) has received FDA approved for Elzonris ahead of the Feb. 21 PDUFA date. The approval coming in two months early highlights “the urgent need” in the indication, according to H.C. Wainwright. The Analyst Analyst Raghuram Selvaraju initiated...
-
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
Saturday, April 21, 2018 - 4:58pm | 435Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares on the Nasdaq in the coming months, according to H.C....
-
HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
Thursday, March 8, 2018 - 4:23pm | 478Analysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments. Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ:...
-
HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology
Wednesday, December 27, 2017 - 2:18pm | 554HTG Molecular Diagnostics Inc (NASDAQ: HTGM), a provider of instruments, reagents and services for molecular profiling, announced Tuesday a new master collaboration agreement with Germany's Merck KGaA(ADR) (OTC: MKKGY). The agreement complements HTG Molecular's previously...
-
What You Should Know About The Drug Approval Valeant Could Receive This Week
Monday, September 18, 2017 - 9:54am | 501Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. Analyst Raghuram Selvaraju reiterated a Neutral rating on the stock with a $17...